Hitgen Ltd., of Chengdu, China, signed a research collaboration with Almirall SA, of Barcelona, Spain, to identify novel small-molecule leads for targets of interest. Hitgen will apply its advanced technology platform, based on DNA-encoded library design, synthesis and screening, to discover leads for Almirall. Under the terms, Hitgen will receive up-front payments, and be eligible for milestone payments from Almirall, though specific financial details were not disclosed.